Skip to content
You are now leaving https://www.ionispharma.com to visit

Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases

CARLSBAD, Calif. , June 5, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it closed its expanded strategic collaboration with Biogen (Nasdaq: BIIB) to discover and develop novel antisense drugs for a broad range of neurological diseases following receipt of